SinoMab BioScienceの収入
SinoMab BioScienceの収入 は何ですか。
SinoMab BioScience Limitedの収入 は-199.64¥です。
収入 の定義は何ですか。
普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
HKSEのセクタHealth Careにおける収入 の企業と比べるSinoMab BioScience
SinoMab BioScienceは何をしますか。
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
SinoMab BioScienceと類似の収入
- Aviva Plcの収入 は-201.00£です。
- Royal Vopak NVの収入 は-200.50€です。
- Molson Coors Canadaの収入 は-200.10$です。
- Molson Coors Canadaの収入 は-200.10$です。
- Federal-Mogul Goetze (India)の収入 は-199.89₨です。
- Service Properties Trustの収入 は-199.68$です。
- SinoMab BioScienceの収入 は-199.64¥です。
- Yanchang Petroleum Internationalの収入 は-199.50HKD$です。
- Xiabuxiabu Catering Management (China) Coの収入 は-199.48¥です。
- Xenon Pharmaceuticals Incの収入 は-199.06$です。
- Arcutis Biotherapeutics Incの収入 は-198.76$です。
- Dacian Goldの収入 は-198.43AUD$です。
- Argo International Ltdの収入 は-198.20$です。